Hennion & Walsh Asset Management Inc. buys 294 shares of AstraZeneca PLC (NASDAQ:AZN)


Hennion & Walsh Asset Management Inc. increased its position in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 6.9% during the first quarter, according to its latest Form 13F filed with the Securities & Exchange. Commission. The fund held 4,544 shares of the company after acquiring an additional 294 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in AstraZeneca were worth $301,000 when it last filed with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the company. RB Capital Management LLC increased its position in AstraZeneca by 1.8% during the first quarter. RB Capital Management LLC now owns 8,381 shares of the company valued at $556,000 after acquiring 151 additional shares in the last quarter. Pinnacle Bancorp Inc. increased its stake in AstraZeneca shares by 13.4% during the first quarter. Pinnacle Bancorp Inc. now owns 1,317 shares of the company valued at $87,000 after purchasing an additional 156 shares during the period. Regal Investment Advisors LLC increased its stake in AstraZeneca shares by 4.8% during the fourth quarter. Regal Investment Advisors LLC now owns 4,038 shares of the company valued at $235,000 after purchasing an additional 185 shares during the period. Clean Yield Group increased its stake in AstraZeneca shares by 3.2% during the first quarter. Clean Yield Group now owns 6,087 shares of the company valued at $404,000 after purchasing an additional 187 shares during the period. Finally, OLD National Bancorp IN increased its stake in AstraZeneca shares by 3.9% during the fourth quarter. OLD National Bancorp IN now owns 5,290 shares of the company valued at $308,000 after purchasing an additional 198 shares during the period. Institutional investors and hedge funds own 20.46% of the company’s shares.

A number of analysts have recently released reports on the stock. Morgan Stanley raised its price target on AstraZeneca shares from £102 ($121.31) to £111 ($132.02) in a Thursday, April 21 research note. Barclays raised its price target on AstraZeneca shares from £115 ($136.77) to £120 ($142.72) in a Thursday April 14 research note. JPMorgan Chase & Co. raised its price target on AstraZeneca shares from £100 ($118.93) to £120 ($142.72) in a Thursday, April 7 research note. Citigroup raised its price target on AstraZeneca shares from £105 ($124.88) to £130 ($154.61) in a research note on Tuesday. Finally, Kepler Capital Markets downgraded AstraZeneca shares from a “buy” rating to a “hold” rating in a Wednesday, May 18 research note. Four investment analysts gave the stock a hold rating and eight gave the company a buy rating. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8,840.50.

AstraZeneca shares opened at $65.08 on Friday. The company has a market capitalization of $201.67 billion, a PE ratio of -203.37, a P/E/G ratio of 1.27 and a beta of 0.44. The company has a debt ratio of 0.77, a quick ratio of 0.66 and a current ratio of 1.00. The company has a 50-day simple moving average of $64.69 and a two-hundred-day simple moving average of $62.92. AstraZeneca PLC has a 1-year low of $53.63 and a 1-year high of $71.70.

AstraZeneca (NASDAQ:AZN – Get Rating) last announced its results on Friday, April 29. The company reported EPS of $0.95 for the quarter, beating analyst consensus estimates of $0.86 by $0.09. The company posted revenue of $11.39 billion in the quarter, versus a consensus estimate of $10.96 billion. AstraZeneca had a negative net margin of 2.56% and a positive return on equity of 25.35%. The company’s revenue increased 55.6% year over year. In the same period a year earlier, the company posted earnings per share of $0.81. On average, stock analysts predict that AstraZeneca PLC will post earnings per share of 3.29 for the current financial year.

AstraZeneca Company Profile (Get a rating)

AstraZeneca PLC, a biopharmaceutical company, is focused on the discovery, development, manufacturing and marketing of prescription drugs. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern and Xigduo/Xigduo XR for cardiovascular, renal and metabolic diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort and Tudorza/Eklira/Bretaris for pulmonology and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq and Ultomiris for rare diseases.

Read more

Want to see which other hedge funds hold AZN? Visit HoldingsChannel.com for the latest 13F filings and insider trading for AstraZeneca PLC (NASDAQ:AZN – Get Rating).

Institutional ownership by quarter for AstraZeneca (NASDAQ:AZN)



Get news and reviews for AstraZeneca Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for AstraZeneca and related companies with MarketBeat.com’s FREE daily email newsletter.

Comments are closed.